Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01363609
Recruitment Status : Completed
First Posted : June 1, 2011
Last Update Posted : February 18, 2015
Sponsor:
Information provided by (Responsible Party):
RG IJzerman, VU University Medical Center

Brief Summary:
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM). Secondly, the aim is to investigate whether treatment with a GLP-1 analog, liraglutide, restores these signals in obese patients with type 2 diabetes. Finally, also the endogenous GLP-1 effects will be investigated in obese individuals before and after gastric bypass surgery on brain satiety and reward systems.

Condition or disease Intervention/treatment Phase
Obesity Type 2 Diabetes Drug: Liraglutide treatment 12 weeks Drug: insulin glargine treatment Drug: GLP-1 receptor antagonist Not Applicable

Detailed Description:

First aim will be addressed in a cross-sectional randomized study. 20 healthy, lean and 20 obese individuals with type 2 diabetes (T2DM) will be exposed to food cues and with concomitant infusion of glucagon Like peptide-1 (GLP-1) receptor antagonist or saline, to assess the involvement of endogenous GLP-1, secreted in response to a meal. Measurements activation of CNS circuits involved in satiety and reward will be performed using blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI).

The second aim will be addressed in cross-over randomized-controlled trial (RCT) in the T2DM patients only. Patients will be randomly assigned liraglutide vs insulin glargine treatment, during a treatment period of 12 weeks each with a 12-week washout period in between. The investigators will perform the same fMRI protocol.

The third aim will be addressed in a study with obese individuals who are scheduled for a gastric bypass surgery. The same protocol as for the first aim will be performed and this will be before and after the surgery in the same individuals.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
Study Start Date : October 2011
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Liraglutide
12 week treatment with liraglutide in fixed dosage
Drug: Liraglutide treatment 12 weeks
liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily

Active Comparator: Insulin glargine
12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
Drug: insulin glargine treatment
Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day

before start of treatment period
before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
Drug: GLP-1 receptor antagonist
Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery




Primary Outcome Measures :
  1. food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%) [ Time Frame: approximately 3 years ]
    • differences between obese T2DM patients and healthy lean subjects food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%)
    • the involvement of endogenous GLP-1 food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%)
    • Effects of treatment with the GLP-1 analog liraglutide in obese patients with type 2 diabetes in food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%)
    • - To investigate the involvement of the increased meal-related endogenous GLP-1 levels after gastric bypass surgery in these food-stimuli related CNS satiety and reward responses and to investigate whether pharmacological blocking of endogenous GLP-1 receptor activation, using a GLP-1 antagonist, differentially affects these responses before and after gastric bypass surgery in obese individuals.


Secondary Outcome Measures :
  1. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in self-reported hunger, satiety, fullness [ Time Frame: approximately 3 years ]
  2. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in basal metabolic rate and post-prandial energy expenditure [ Time Frame: approximately 3 years ]
  3. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in microvascular function and vasomotion [ Time Frame: approximately 3 years ]
  4. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in cardiovascular autonomic nervous balance [ Time Frame: approximately 3 years ]
  5. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in concomitant changes in metabolic and humoral markers [ Time Frame: approximately 3 years ]
  6. Alterations in resting state brain activity networks in obese patients with type 2 diabetes compared to lean, healthy individuals and the involvement of endogenous GLP-1 [ Time Frame: approximately 3 years ]
  7. Alterations in brain arterial blood flow in obese patients with type 2 diabetes compared to lean, healthy individuals and the involvement of endogenous GLP-1 [ Time Frame: approximately 3 years ]
  8. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in resting state brain activity networks. [ Time Frame: approximately 3 years ]
  9. GLP-1 analog treatment related changes in obese patients with type 2 diabetes in brain arterial blood flow. [ Time Frame: approximately 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • For the healthy, lean individuals:
  • Age 18-65 years
  • Women: post menopausal (excluding possible menstruation cycle effects)
  • Body-mass index (BMI) of <25 kg/m2,
  • Stable bodyweight (<5% reported change during the previous 3 months).
  • Normal fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (34)
  • Right handed

For the obese T2DM individuals:

  • Age 18-65 years
  • Women: post menopausal (excluding possible menstruation cycle effects)
  • BMI 25-40 kg/m2
  • Stable bodyweight (<5% reported change during the previous 3 months).
  • Diagnosed with T2DM > 3 months prior to screening
  • HbA1C 6.5-8.5%
  • Treatment with metformin at a stable dose for at least 3 months.
  • Right handed

For the obese individuals scheduled for gastric bypass surgery:

  • Age 18-65 years
  • Women: preferably post menopausal (excluding possible menstruation cycle effects)
  • Body-mass index (BMI) of >30 kg/m2,
  • Stable bodyweight (<5% reported change during the previous 1 months).
  • Normal or impaired fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (defined as glucose fasting < 7.1 mmol/l and after OGTT t=120min < 11.0 mmol/l) (39)
  • Right handed

Exclusion Criteria:

  • GLP-1 based therapies, thiazolidinediones, sulphonylurea or insulin within 3 months before screening
  • Weight-lowering agents within 3 months before screening.
  • Congestive heart failure (NYHA II-IV)
  • Chronic renal failure (glomerular filtration rate < 60 mL/min/1.73m2 per Modification of Diet in Renal Disease (MDRD))
  • Liver disease
  • History of gastrointestinal disorders (including gastropareses, pancreatitis and cholelithiasis)
  • Neurological illness
  • Malignancy
  • Other type of bariatric surgery (Redo-GBP, sleeve, distal GBP, adj banding, Scopinaro)
  • History of major heart disease
  • History of major renal disease
  • Pregnancy or breast feeding
  • Implantable devices
  • Substance abuse
  • Addiction
  • Contra-indication for MRI, such as claustrophobia or pacemaker
  • Any psychiatric illness; including eating disorders and depression
  • Chronic use of centrally acting agents or glucocorticoids within 2 weeks immediately prior to screening.
  • Use of cytostatic or immune modulatory agents
  • History or known allergy for acetaminophen.
  • History of allergy for insulin analog
  • History of allergy for liraglutide
  • Participation in other studies
  • Individuals who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  • Individuals who are investigator site personnel, directly affiliated with the study, or are immediate family

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01363609


Locations
Layout table for location information
Netherlands
VU University Medical Center
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
VU University Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: RG IJzerman, MD, PhD, VU University Medical Center
ClinicalTrials.gov Identifier: NCT01363609    
Other Study ID Numbers: DC2011LiBrain001
First Posted: June 1, 2011    Key Record Dates
Last Update Posted: February 18, 2015
Last Verified: February 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Glargine
Liraglutide
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists